Tired-looking droopy eyelids got you down?
Take the first step against low lying eyelids.
Have you noticed a change in the appearance of your eyes, where your lids are starting to droop? You may have acquired ptosis, or low-lying lids.
Acquired ptosis (low-lying lids) is a common medical condition that:
Affects adults of all ages, but occurs more often with increased age.
Usually occurs when the muscles in the eyelid stretch and weaken, causing the upper eyelid to droop and causing asymmetrical eyes.
May be caused by other issues, such as cataract surgery, contact lens wear, or an underlying medical condition. It could also be a sign of a more serious medical condition.
In clinical trials, Upneeq® helped patients with acquired ptosis on the first day of treatment!
87% of patients had some form of improvement.
74% of patients had at least a 50% improvement on Day 14 (2 hours after applying Upneeq®).
UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1 % contains oxymetazoline hydrochloride, an alpha adrenoceptor agonist and is FDA approved for the treatment of acquired blepharoptosis (low-lying eyelids) in adults. Acquired ptosis can develop later in life and usually occurs when muscles in the eyelid stretch and weaken, causing the lid to droop. Eyelid ptosis may be caused by other issues, such as cataract surgery, contact lens wear, or an underlying medical condition. Eyelid ptosis can affect eyesight by not only blocking your vision, but also by reducing field of vision
Please note, Upneeq® is a prescription product.
Each box contains 48, 0.3 mL single use applicators in individual child-resistant foil pouches.
TSA Friendly: Yes
How to Use:
Apply Upneeq ® to your affected eye(s) in 2 easy steps
Step 1: Cut open foil wrapper and remove single-use vial
Step 2: Apply one drop of Upneeq ® in each affected eye as directed, once a day. Do not let the tip of the vial touch your eye or any other surface. Vials should not be re-used after opening and should be thrown away after applying drop(s).
Wash hands thoroughly before using Upneeq ®.
Shake the vial well before inserting drops.
Upneeq ® should only be used as directed.
Upneeq ® is designed to only be applied as an eyedrop.
If you wear contact lenses, remove them before applying Upneeq ® eyedrops.
You may put contact lenses back in 15 minutes after applying Upneeq ®.
If more than one topical ophthalmic drug is being used, the drugs should be administered at least 15 minutes between applications.
Each vial contains enough Upneeq ® solution to allow for one drop in each affected eye. The solution should never be swallowed or ingested in any other way.
Storage requirements: Upneeq ® should be stored at 68°F-77°F (20°C-25°C) and should be protected from excessive heat.
Keep out of reach of children.
UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%
contains oxymetazoline hydrochloride, an alpha adrenoceptor agonist. UPNEEQ ® is an aseptically prepared, sterile, nonpreserved ophthalmic solution. Each mL of UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution) 0.1% contains 1 mg of oxymetazoline hydrochloride, equivalent to 0.09 mg (0.09%) of oxymetazoline free base. The ophthalmic solution contains the following inactive ingredients: calcium chloride, hydrochloric acid (used to adjust pH to 5.8 to 6.8), hypromellose, magnesium chloride, potassium chloride, sodium acetate, sodium chloride, sodium citrate, and water for injection.
Frequently asked questions: